Skip to main content
. 2019 Nov 28;9:17792. doi: 10.1038/s41598-019-54513-3

Figure 1.

Figure 1

Estimated survival among the NSCLC synchronous brain metastasis population, SEER-Medicare dataset 2010–2012; For NSCLC patients diagnosed with brain metastases, the top panel in this figure shows a Kaplan-Meier estimate of survival for each group of patients treated with and without bevacizumab, and the middle panel shows a conditional survival curve in which each observation is weighted with respect to odds of bevacizumab treatment. At the bottom, a table describes the Kaplan-Meier estimated proportion of patients at risk is provided.